With revenues for fiscal year 2003 looking 30 percent to 45 percent leaner than expected, Lion Bioscience will be facing some tough choices as it aims to break even by the last quarter of FY 2004 — a target CEO Friedrich von Bohlen insists the company will meet.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.